IDEAS home Printed from https://ideas.repec.org/a/gam/jijerp/v18y2021i23p12636-d691832.html
   My bibliography  Save this article

β-Glucans Could Be Adjuvants for SARS-CoV-2 Virus Vaccines (COVID-19)

Author

Listed:
  • Alfredo Córdova-Martínez

    (Department of Biochemistry, Molecular Biology and Physiology, Faculty of Health Sciences, GIR: “Physical Exercise and Ageing”, University Campus “Los Pajaritos”, Valladolid University, 42004 Soria, Spain)

  • Alberto Caballero-García

    (Department of Anatomy and Radiology, Faculty of Health Sciences, GIR: “Physical Exercise and Ageing”, University Campus “Los Pajaritos”, Valladolid University, 42004 Soria, Spain)

  • Enrique Roche

    (Department of Applied Biology-Nutrition, Institute of Bioengineering, Miguel Hernández University, 03202 Elche, Spain
    Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), 03010 Alicante, Spain
    CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain)

  • David C. Noriega

    (Spine Unit, Department of Surgery, Ophthalmology, Otorhinolaryngology and Physiotherapy, Faculty of Medicine, Hospital Clínico Universitario de Valladolid, 47003 Valladolid, Spain)

Abstract

Waiting for an effective treatment against the SARS-CoV-2 virus (the cause of COVID-19), the current alternatives include prevention and the use of vaccines. At the moment, vaccination is the most effective strategy in the fight against pandemic. Vaccines can be administered with different natural biological products (adjuvants) with immunomodulating properties. Adjuvants can be taken orally, complementing vaccine action. Adjuvant compounds could play a key role in alleviating the symptoms of the disease, as well as in enhancing vaccine action. Adjuvants also contribute to an effective immune response and can enhance the protective effect of vaccines in immunocompromised individuals such as the elderly. Adjuvants must not produce adverse effects, toxicity, or any other symptoms that could alter immune system function. Vaccine adjuvants are substances of wide varying chemical structure that are used to boost the immune response against a simultaneously administered antigen. Glucans could work as adjuvants due to their immunomodulatory biological activity. In this respect, β-(1,3)-(1,6) glucans are considered the most effective and safe according to the list issued by the European Commission. Only glucans with a β-(1,3) bond linked to a β-(1,6) are considered modulators of certain biological responses. The aim of this review is to present the possible effects of β-glucans as adjuvants in the efficacy of vaccines against SARS-CoV-2 virus.

Suggested Citation

  • Alfredo Córdova-Martínez & Alberto Caballero-García & Enrique Roche & David C. Noriega, 2021. "β-Glucans Could Be Adjuvants for SARS-CoV-2 Virus Vaccines (COVID-19)," IJERPH, MDPI, vol. 18(23), pages 1-13, November.
    • Handle: RePEc:gam:jijerp:v:18:y:2021:i:23:p:12636-:d:691832
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/1660-4601/18/23/12636/pdf
    Download Restriction: no
    File URL: https://www.mdpi.com/1660-4601/18/23/12636/
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Ewen Callaway, 2020. "The race for coronavirus vaccines: a graphical guide," Nature, Nature, vol. 580(7805), pages 576-577, April.
    2. Florian Krammer, 2020. "SARS-CoV-2 vaccines in development," Nature, Nature, vol. 586(7830), pages 516-527, October.
    3. Olaf Gross & Andreas Gewies & Katrin Finger & Martin Schäfer & Tim Sparwasser & Christian Peschel & Irmgard Förster & Jürgen Ruland, 2006. "Card9 controls a non-TLR signalling pathway for innate anti-fungal immunity," Nature, Nature, vol. 442(7103), pages 651-656, August.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Tang, Lianhua & Li, Yantong & Bai, Danyu & Liu, Tao & Coelho, Leandro C., 2022. "Bi-objective optimization for a multi-period COVID-19 vaccination planning problem," Omega, Elsevier, vol. 110(C).
    2. Arielle Kaim & Maya Siman-Tov & Eli Jaffe & Bruria Adini, 2021. "From Isolation to Containment: Perceived Fear of Infectivity and Protective Behavioral Changes during the COVID-19 Vaccination Campaign," IJERPH, MDPI, vol. 18(12), pages 1-12, June.
    3. Laura Pérez-Alós & Cecilie Bo Hansen & Jose Juan Almagro Armenteros & Johannes Roth Madsen & Line Dam Heftdal & Rasmus Bo Hasselbalch & Mia Marie Pries-Heje & Rafael Bayarri-Olmos & Ida Jarlhelt & Seb, 2023. "Previous immunity shapes immune responses to SARS-CoV-2 booster vaccination and Omicron breakthrough infection risk," Nature Communications, Nature, vol. 14(1), pages 1-15, December.
    4. Yao Yu & Rong-Rong Wang & Nai-Jun Miao & Jia-Jie Tang & Yun-Wei Zhang & Xiang-Ran Lu & Pei-Yi Yan & Jing Wang & Xin-Ming Jia, 2022. "PD-L1 negatively regulates antifungal immunity by inhibiting neutrophil release from bone marrow," Nature Communications, Nature, vol. 13(1), pages 1-16, December.
    5. Charles B. Stauft & Prabhuanand Selvaraj & Felice D’Agnillo & Clement A. Meseda & Shufeng Liu & Cyntia L. Pedro & Kotou Sangare & Christopher Z. Lien & Jerry P. Weir & Matthew F. Starost & Tony T. Wan, 2023. "Intranasal or airborne transmission-mediated delivery of an attenuated SARS-CoV-2 protects Syrian hamsters against new variants," Nature Communications, Nature, vol. 14(1), pages 1-17, December.
    6. Motta, Matt, 2021. "Can a COVID-19 vaccine live up to Americans’ expectations? A conjoint analysis of how vaccine characteristics influence vaccination intentions," Social Science & Medicine, Elsevier, vol. 272(C).
    7. Sun Jin Kim & Zhong Yao & Morgan C. Marsh & Debra M. Eckert & Michael S. Kay & Anna Lyakisheva & Maria Pasic & Aiyush Bansal & Chaim Birnboim & Prabhat Jha & Yannick Galipeau & Marc-André Langlois & J, 2022. "Homogeneous surrogate virus neutralization assay to rapidly assess neutralization activity of anti-SARS-CoV-2 antibodies," Nature Communications, Nature, vol. 13(1), pages 1-9, December.
    8. Anneliese S. Ashhurst & Matt D. Johansen & Joshua W. C. Maxwell & Skye Stockdale & Caroline L. Ashley & Anupriya Aggarwal & Rezwan Siddiquee & Stefan Miemczyk & Duc H. Nguyen & Joel P. Mackay & Claudi, 2022. "Mucosal TLR2-activating protein-based vaccination induces potent pulmonary immunity and protection against SARS-CoV-2 in mice," Nature Communications, Nature, vol. 13(1), pages 1-18, December.
    9. Tomohiro Takano & Takashi Sato & Ryutaro Kotaki & Saya Moriyama & Shuetsu Fukushi & Masahiro Shinoda & Kiyomi Kabasawa & Nagashige Shimada & Mio Kousaka & Yu Adachi & Taishi Onodera & Kazutaka Terahar, 2023. "Heterologous SARS-CoV-2 spike protein booster elicits durable and broad antibody responses against the receptor-binding domain," Nature Communications, Nature, vol. 14(1), pages 1-13, December.
    10. Phanramphoei N. Frantz & Aleksandr Barinov & Claude Ruffié & Chantal Combredet & Valérie Najburg & Guilherme Dias de Melo & Florence Larrous & Lauriane Kergoat & Samaporn Teeravechyan & Anan Jongkaeww, 2021. "A live measles-vectored COVID-19 vaccine induces strong immunity and protection from SARS-CoV-2 challenge in mice and hamsters," Nature Communications, Nature, vol. 12(1), pages 1-17, December.
    11. Piñeiro-Chousa, Juan & López-Cabarcos, M. Ángeles & Quiñoá-Piñeiro, Lara & Pérez-Pico, Ada M., 2022. "US biopharmaceutical companies' stock market reaction to the COVID-19 pandemic. Understanding the concept of the ‘paradoxical spiral’ from a sustainability perspective," Technological Forecasting and Social Change, Elsevier, vol. 175(C).
    12. Andersson, Ola & Campos-Mercade, Pol & Meier, Armando N. & Wengström, Erik, 2021. "Anticipation of COVID-19 vaccines reduces willingness to socially distance," Journal of Health Economics, Elsevier, vol. 80(C).
    13. Fulvio Lauretani & Marco Salvi & Irene Zucchini & Crescenzo Testa & Chiara Cattabiani & Arianna Arisi & Marcello Maggio, 2023. "Relationship between Vitamin D and Immunity in Older People with COVID-19," IJERPH, MDPI, vol. 20(8), pages 1-19, April.
    14. Anahita Fathi & Christine Dahlke & Verena Krähling & Alexandra Kupke & Nisreen M. A. Okba & Matthijs P. Raadsen & Jasmin Heidepriem & Marcel A. Müller & Grigori Paris & Susan Lassen & Michael Klüver &, 2022. "Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndrome," Nature Communications, Nature, vol. 13(1), pages 1-12, December.
    15. Lening A. Olivera-Figueroa & Alexander Unger & Julie Papastamatelou & Philip G. Zimbardo, 2023. "A Time to Get Vaccinated? The Role of Time Perspective, Consideration of Future Consequences, Conspiracy Beliefs, Religious Faith, Gender, and Race on Intention to Vaccinate for COVID-19 in the United," IJERPH, MDPI, vol. 20(4), pages 1-23, February.
    16. Carlos Ávila-Nieto & Júlia Vergara-Alert & Pep Amengual-Rigo & Erola Ainsua-Enrich & Marco Brustolin & María Luisa Rodríguez de la Concepción & Núria Pedreño-Lopez & Jordi Rodon & Victor Urrea & Edwar, 2024. "Immunization with V987H-stabilized Spike glycoprotein protects K18-hACE2 mice and golden Syrian hamsters upon SARS-CoV-2 infection," Nature Communications, Nature, vol. 15(1), pages 1-18, December.
    17. See Ming Lim & Hwang Ching Chan & Amelia Santosa & Swee Chye Quek & Eugene Hern Choon Liu & Jyoti Somani, 2022. "Role of Occupational Health Services in Planning and Implementing of Staff COVID-19 Vaccination Clinic: A Tertiary Hospital Experience in Singapore," IJERPH, MDPI, vol. 19(21), pages 1-10, October.
    18. Abdulaziz Alhazmi & Edrous Alamer & Siddig Abdelwahab & Nizar Khamjan & Abdullah Hamami & Moayad Haddad & Majid Darraj & Anwar M. Hashem & Abdullah Algaissi, 2021. "Community-Based Seroprevalence of SARS-CoV-2 Antibodies following the First Wave of the COVID-19 Pandemic in Jazan Province, Saudi Arabia," IJERPH, MDPI, vol. 18(23), pages 1-9, November.
    19. Matthias Reinscheid & Hendrik Luxenburger & Vivien Karl & Anne Graeser & Sebastian Giese & Kevin Ciminski & David B. Reeg & Valerie Oberhardt & Natascha Roehlen & Julia Lang-Meli & Kathrin Heim & Nina, 2022. "COVID-19 mRNA booster vaccine induces transient CD8+ T effector cell responses while conserving the memory pool for subsequent reactivation," Nature Communications, Nature, vol. 13(1), pages 1-11, December.
    20. Torben Mentrup & Anna Yamina Stumpff-Niggemann & Nadja Leinung & Christine Schlosser & Katja Schubert & Rebekka Wehner & Antje Tunger & Valentin Schatz & Patrick Neubert & Ann-Christine Gradtke & Jani, 2022. "Phagosomal signalling of the C-type lectin receptor Dectin-1 is terminated by intramembrane proteolysis," Nature Communications, Nature, vol. 13(1), pages 1-18, December.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:18:y:2021:i:23:p:12636-:d:691832. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.